

ACORDA THERAPEUTICS INC

Reported by
CARRAZANA ENRIQUE J.

FORM 4

(Statement of Changes in Beneficial Ownership)

Filed 01/12/15 for the Period Ending 01/08/15

| | |
|-------------|--|
| Address | 420 SAW MILL RIVER ROAD ARDSLEY, NY 10502 |
| Telephone | 914-347-4300 |
| CIK | 0001008848 |
| Symbol | ACOR |
| SIC Code | 2836 - Biological Products, Except Diagnostic Substances |
| Industry | Biotechnology & Drugs |
| Sector | Healthcare |
| Fiscal Year | 12/31 |

FORM 4

**UNITED STATES SECURITIES AND EXCHANGE
COMMISSION
Washington, D.C. 20549**

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5

[] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

| | | |
|--|---|--|
| 1. Name and Address of Reporting Person * Carrazana Enrique J. (Last) (First) (Middle) 420 SAW MILL RIVER ROAD (Street) ARDSLEY, NY 10502 (City) (State) (Zip) | 2. Issuer Name and Ticker or Trading Symbol ACORDA THERAPEUTICS INC [ACOR] | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input type="checkbox"/> Director <input type="checkbox"/> 10% Owner <input checked="" type="checkbox"/> Officer (give title below) <input type="checkbox"/> Other (specify below) Chief Medical Officer |
| 3. Date of Earliest Transaction (MM/DD/YYYY) <p align="center">1/8/2015</p> | | 6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person |
| 4. If Amendment, Date Original Filed (MM/DD/YYYY) | | |

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

| 1. Title of Security (Instr. 3) | 2. Trans. Date | 2A. Deemed Execution Date, if any | 3. Trans. Code (Instr. 8) | | 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | | | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) |
|---------------------------------|----------------|-----------------------------------|---------------------------|---|---|------------|---------------|---|--|---|
| | | | Code | V | Amount | (A) or (D) | Price | | | |
| Common Stock | 1/8/2015 | | M | | 6715 (1) | A | \$30.46 | 40209 | D | |
| Common Stock | 1/8/2015 | | S | | 6715 (1) | D | \$42.0058 (2) | 33494 | D | |
| Common Stock | 1/9/2015 | | M | | 16803 (1) | A | \$30.46 | 50297 | D | |
| Common Stock | 1/9/2015 | | M | | 18225 (1) | A | \$26.35 | 68522 | D | |
| Common Stock | 1/9/2015 | | M | | 42879 (1) | A | \$21.52 | 111401 | D | |
| Common Stock | 1/9/2015 | | S | | 77907 (1) | D | \$42.1058 (3) | 33494 | D | |
| Common Stock | 1/12/2015 | | M | | 13371 (1) | A | \$21.52 | 46865 | D | |
| Common Stock | 1/12/2015 | | S | | 8200 (1) | D | \$42.6097 (4) | 38665 | D | |
| Common Stock | 1/12/2015 | | S | | 5171 (1) | D | \$43.5045 (5) | 33494 | D | |

Table II - Derivative Securities Beneficially Owned (e.g. , puts, calls, warrants, options, convertible securities)

| 1. Title of Derivate Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Trans. Date | 3A. Deemed Execution Date, if any | 4. Trans. Code (Instr. 8) | | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | | 6. Date Exercisable and Expiration Date | | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction (s) (Instr. 4) | 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |
|--|--|----------------|-----------------------------------|---------------------------|---|--|-----|---|-----------------|---|----------------------------|--|---|--|--|
| | | | | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | | | | |
| Employee Stock Option (right to buy) | \$30.46 | 1/8/2015 | | M | | 6715 (1) | | (6) | 3/6/2023 | Common Stock | 6715 | \$0.00 | 40320 | D | |

Table II - Derivative Securities Beneficially Owned (e.g. , puts, calls, warrants, options, convertible securities)

| 1. Title of Derivate Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Trans. Date | 3A. Deemed Execution Date, if any | 4. Trans. Code (Instr. 8) | | | | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | | 6. Date Exercisable and Expiration Date | | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction (s) (Instr. 4) | 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |
|--|--|----------------|-----------------------------------|---------------------------|---|-----|-----------|--|-----------------|---|----------------------------|---|-------|--|---|--|--|
| | | | | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | | | | | | |
| Employee Stock Option (right to buy) | \$30.46 | 1/9/2015 | | M | | | 16803 (1) | (6) | 3/6/2023 | Common Stock | 16803 | \$0.00 | 23517 | D | | | |
| Employee Stock Option (right to buy) | \$26.35 | 1/9/2015 | | M | | | 18225 (1) | (7) | 3/15/2022 | Common Stock | 18225 | \$0.00 | 6075 | D | | | |
| Employee Stock Option (right to buy) | \$21.52 | 1/9/2015 | | M | | | 42879 (1) | (8) | 10/15/2021 | Common Stock | 42879 | \$0.00 | 32121 | D | | | |
| Employee Stock Option (right to buy) | \$21.52 | 1/12/2015 | | M | | | 13371 (1) | (8) | 10/15/2021 | Common Stock | 13371 | \$0.00 | 18750 | D | | | |

Explanation of Responses:

- (1) Exercise and sales pursuant to a 10b5-1 plan.
- (2) The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from \$42.00 to \$42.13 per share. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- (3) The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from \$42.00 to \$42.31 per share. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- (4) The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from \$42.16 to \$43.15 per share. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- (5) The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from \$43.23 to \$43.80 per share. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- (6) The shares subject to this option vest in equal quarterly installments over four years beginning on January 1, 2013 with the first quarterly installment vested on April 1, 2013.
- (7) The shares subject to this option vest in equal quarterly installments over four years beginning on January 1, 2012 with the first quarterly installment vested on April 1, 2012.
- (8) 25% of the shares subject to this option vested on October 15, 2012. The balance of the shares subject to this option vest in equal quarterly installments over the three years thereafter.

Reporting Owners

| Reporting Owner Name / Address | Relationships | | | |
|--|---------------|-----------|-----------------------|-------|
| | Director | 10% Owner | Officer | Other |
| Carrazana Enrique J. 420 SAW MILL RIVER ROAD ARDSLEY, NY 10502 | | | Chief Medical Officer | |

Signatures

/s/ Enrique Carrazana

1/12/2015

Date

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently

valid OMB control number.